Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?

Jan Menne

doi:10.1016/j.kint.2020.03.011

Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?

Kidney Int. 2020 Jun;97(6):1106-1108. doi: 10.1016/j.kint.2020.03.011.

Author

Jan Menne¹

Affiliation

¹ Department of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany. Electronic address: [email protected].

PMID: 32444092
DOI: 10.1016/j.kint.2020.03.011

Abstract

Ravulizumab, a new long-acting C5 inhibitor, recently received FDA approval for the treatment of aHUS. Rates of complete thrombotic microangiopathy response were similar to those observed in major eculizumab trials; however, fewer patients in the ravulizumab study were able to stop dialysis, probably due to differences in the study populations. Until additional data/analyses are available, eculizumab remains the drug of choice for an acute aHUS episode, whereas ravulizumab has several advantages in maintenance treatment.

MeSH terms

Antibodies, Monoclonal, Humanized
Atypical Hemolytic Uremic Syndrome* / drug therapy
Humans
Remission Induction
Renal Dialysis

Substances

Antibodies, Monoclonal, Humanized
ravulizumab